A phase I/II study of the CXCR2 inhibitor, AZD5069, in combination with durvalumab, in patients (pts) with advanced hepatocellular carcinoma (HCC).

出版年份 2023 全文链接

标题

作者

关键词

出版物

Volume 41, Issue 4_suppl, Pages TPS631-TPS631

出版商

American Society of Clinical Oncology (ASCO)

发表日期

2023-01-25

DOI

10.1200/jco.2023.41.4_suppl.tps631

Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.

Upload Now

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now